Literature DB >> 23795307

Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease.

Jessica Ciesler1, Youssef Sari.   

Abstract

Neurodegenerative diseases are characterized by the progressive loss of neurons and glial cells in the central nervous system correlated to their symptoms. Among these neurodegenerative diseases are Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Neurodegeneration is mostly restricted to specific neuronal populations: cholinergic neurons in AD and motoneurons in ALS. The demonstration that the onset and progression of neurodegenerative diseases in models of transgenic mice, in particular, is delayed or improved by the application of neurotrophic factors and derived peptides from neurotrophic factors has emphasized their importance in neurorestoration. A range of neurotrophic factors and growth peptide factors derived from activity-dependent neurotrophic factor/activity-dependent neuroprotective protein has been suggested to restore neuronal function, improve behavioral deficits and prolong the survival in animal models. In this review article, we focus on the role of trophic peptides in the improvement of AD and ALS. An understanding of the molecular pathways involved with trophic peptides in these neurodegenerative diseases may shed light on potential therapies.

Entities:  

Keywords:  ADNF-9; Alzheimer’s disease; Amyotrophic Lateral Sclerosis; Colivelin; NAP

Year:  2013        PMID: 23795307      PMCID: PMC3686488          DOI: 10.13055/ojns_3_1_2.130408

Source DB:  PubMed          Journal:  Open J Neurosci        ISSN: 2075-9088


  80 in total

Review 1.  Neurotrophin signalling in health and disease.

Authors:  Moses V Chao; Rithwick Rajagopal; Francis S Lee
Journal:  Clin Sci (Lond)       Date:  2006-02       Impact factor: 6.124

Review 2.  Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Authors:  Natalia Shiryaev; Regina Pikman; Eliezer Giladi; Illana Gozes
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

Review 4.  A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.

Authors:  I Gozes; M Bassan; R Zamostiano; A Pinhasov; A Davidson; E Giladi; O Perl; G W Glazner; D E Brenneman
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 5.  Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis.

Authors:  Masaaki Matsuoka; Yuichi Hashimoto; Sadakazu Aiso; Ikuo Nishimoto
Journal:  CNS Drug Rev       Date:  2006

6.  Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo.

Authors:  Tomohiro Chiba; Marina Yamada; Yuichi Hashimoto; Maiko Sato; Jumpei Sasabe; Yoshiko Kita; Kenzo Terashita; Sadakazu Aiso; Ikuo Nishimoto; Masaaki Matsuoka
Journal:  J Neurosci       Date:  2005-11-02       Impact factor: 6.167

7.  Humanin peptide suppresses apoptosis by interfering with Bax activation.

Authors:  Bin Guo; Dayong Zhai; Edelmira Cabezas; Kate Welsh; Shahrzad Nouraini; Arnold C Satterthwait; John C Reed
Journal:  Nature       Date:  2003-05-04       Impact factor: 49.962

8.  Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice.

Authors:  Masaoki Kawasumi; Tomohiro Chiba; Marina Yamada; Makiko Miyamae-Kaneko; Masaaki Matsuoka; Jin Nakahara; Taisuke Tomita; Takeshi Iwatsubo; Shigeaki Kato; Sadakazu Aiso; Ikuo Nishimoto; Keisuke Kouyama
Journal:  Eur J Neurosci       Date:  2004-05       Impact factor: 3.386

9.  The influence of insulin infusion on the metabolism of amyloid β peptides in plasma.

Authors:  Monika Karczewska-Kupczewska; Natalia Lelental; Agnieszka Adamska; Agnieszka Nikołajuk; Irina Kowalska; Maria Górska; Rüdiger Zimmermann; Johannes Kornhuber; Marek Strączkowski; Piotr Lewczuk
Journal:  Alzheimers Dement       Date:  2012-10-27       Impact factor: 21.566

Review 10.  From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.

Authors:  Illana Gozes; Inna Divinsky; Inbar Pilzer; Mati Fridkin; Douglas E Brenneman; Avron D Spier
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more
  8 in total

1.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

2.  Caspase-8 Mediates Amyloid-β-induced Apoptosis in Differentiated PC12 Cells.

Authors:  Min-cai Qian; Jing Liu; Jia-shu Yao; Wei-min Wang; Jian-hong Yang; Li-li Wei; Yue-di Shen; Wei Chen
Journal:  J Mol Neurosci       Date:  2015-02-03       Impact factor: 3.444

Review 3.  Amyotrophic Lateral Sclerosis: New Perpectives and Update.

Authors:  Marco Orsini; Acary Bulle Oliveira; Osvaldo J M Nascimento; Carlos Henrique Melo Reis; Marco Antonio Araujo Leite; Jano Alves de Souza; Camila Pupe; Olivia Gameiro de Souza; Victor Hugo Bastos; Marcos R G de Freitas; Silmar Teixeira; Carlos Bruno; Eduardo Davidovich; Benny Smidt
Journal:  Neurol Int       Date:  2015-09-24

4.  BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR.

Authors:  Vishruti Makani; Yong-Gil Jang; Kevin Christopher; Wesley Judy; Jacob Eckstein; Kenneth Hensley; Nicolas Chiaia; Dong-Shik Kim; Joshua Park
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

5.  Safety and Feasibility of Lin- Cells Administration to ALS Patients: A Novel View on Humoral Factors and miRNA Profiles.

Authors:  Anna Sobuś; Bartłomiej Baumert; Zofia Litwińska; Monika Gołąb-Janowska; Jacek Stępniewski; Maciej Kotowski; Ewa Pius-Sadowska; Miłosz P Kawa; Dorota Gródecka-Szwajkiewicz; Jarosław Peregud-Pogorzelski; Józef Dulak; Przemysław Nowacki; Bogusław Machaliński
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

6.  Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures.

Authors:  Sara Hernando; Polyxeni Nikolakopoulou; Dimitrios Voulgaris; Rosa Maria Hernandez; Manoli Igartua; Anna Herland
Journal:  Fluids Barriers CNS       Date:  2022-03-17

7.  Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report.

Authors:  Wioletta Pawlukowska; Bartłomiej Baumert; Monika Gołąb-Janowska; Ewa Pius-Sadowska; Zofia Litwińska; Maciej Kotowski; Agnieszka Meller; Iwona Rotter; Jarosław Peregud-Pogorzelski; Przemysław Nowacki
Journal:  Int J Med Sci       Date:  2020-07-19       Impact factor: 3.738

8.  Mini-GAGR, an intranasally applied polysaccharide, activates the neuronal Nrf2-mediated antioxidant defense system.

Authors:  Kelsey Murphy; Killian Llewellyn; Samuel Wakser; Josef Pontasch; Natasha Samanich; Matthew Flemer; Kenneth Hensley; Dong-Shik Kim; Joshua Park
Journal:  J Biol Chem       Date:  2018-10-03       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.